Suppr超能文献

p57 表达缺失和 RhoA 过表达与肝癌患者的不良预后相关。

Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.

机构信息

Department of Oncology, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 71006, P.R. China.

出版信息

Oncol Rep. 2013 Oct;30(4):1707-14. doi: 10.3892/or.2013.2608. Epub 2013 Jul 9.

Abstract

p57 and Ras homology A (RhoA) have been implicated in the growth and metastasis of several types of human cancers. This study aimed to detect their expression in hepatocellular carcinoma (HCC) tissue specimens and to determine a possible association with clinicopathological data and patient survival. A total of 80 HCC and corresponding distant normal tissue specimens were processed for immunohistochemical and qPCR analyses of p57 and RhoA expression. The data showed that expression of p57 mRNA and protein was reduced in HCC tissues when compared to that in distant non-cancer tissues (P<0.05), while expression of RhoA mRNA and protein was significantly higher in HCC tissue specimens when compared to that of the distant normal tissues. Loss of p57 expression was associated with HCC with higher α-fetoprotein (AFP) levels (>400 ng/ml; P=0.044), larger tumor size (>5 cm, P=0.004), poor tumor differentiation (P=0.020), advanced TNM stage (P=0.027), capsule invasion (P=0.018) and tumor thrombosis (P=0.008), whereas expression of RhoA protein was significantly associated with poor tumor differentiation (P=0.042), capsule invasion (P=0.022), and tumor thrombosis (P=0.002). Furthermore, there was a strong inverse relationship between p57 and RhoA expression in HCC tissues, indicating that loss of p57 expression may contribute to RhoA overexpression in HCC tissues. The median survival time of HCC patients with p57+ and p57- expression was 13.0 and 9.0 months, respectively, whereas the median survival time of HCC patients with RhoA+ and RhoA- was 9.0 and 15.0 months. Univariate analysis revealed that the levels of AFP, tumor size, TNM stage, histological grade, capsule invasion, tumor thrombosis, p57, RhoA and co-expression of p57 and RhoA were all significant prognostic indicators for overall survival of HCC patients. Multivariate analysis showed that tumor size, TNM stage, p57, RhoA and combined loss of p57 with RhoA were risk factors for poor survival of HCC patients. This study indicates that the abnormal expression of p57 and RhoA contributes to progression of HCC and poor survival of patients.

摘要

p57 和 Ras 同源物 A(RhoA)已被牵连到几种类型的人类癌症的生长和转移中。本研究旨在检测其在肝细胞癌(HCC)组织标本中的表达,并确定与临床病理数据和患者生存的可能关联。总共处理了 80 个 HCC 和相应的远处正常组织标本,以进行 p57 和 RhoA 表达的免疫组织化学和 qPCR 分析。数据显示,与远处非癌组织相比,HCC 组织中 p57 mRNA 和蛋白的表达降低(P<0.05),而 RhoA mRNA 和蛋白的表达在 HCC 组织标本中明显高于远处正常组织。p57 表达缺失与 AFP 水平较高(>400ng/ml;P=0.044)、肿瘤较大(>5cm,P=0.004)、肿瘤分化不良(P=0.020)、TNM 分期较晚(P=0.027)、包膜侵犯(P=0.018)和肿瘤血栓形成(P=0.008)相关,而 RhoA 蛋白的表达与肿瘤分化不良(P=0.042)、包膜侵犯(P=0.022)和肿瘤血栓形成(P=0.002)显著相关。此外,HCC 组织中 p57 和 RhoA 表达之间存在强烈的负相关关系,表明 p57 表达缺失可能导致 HCC 组织中 RhoA 过表达。p57+和 p57-表达的 HCC 患者的中位生存时间分别为 13.0 个月和 9.0 个月,而 RhoA+和 RhoA-的 HCC 患者的中位生存时间分别为 9.0 个月和 15.0 个月。单因素分析显示,AFP、肿瘤大小、TNM 分期、组织学分级、包膜侵犯、肿瘤血栓形成、p57、RhoA 以及 p57 和 RhoA 的共表达水平均为 HCC 患者总生存的显著预后指标。多因素分析显示,肿瘤大小、TNM 分期、p57、RhoA 以及联合缺失 p57 与 RhoA 是 HCC 患者不良生存的危险因素。本研究表明,p57 和 RhoA 的异常表达有助于 HCC 的进展和患者的不良生存。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验